Company: BIAF
Filing Date: 2025-04-11
Form Type: S-1
Source: 0001641172-25-003892
Chunk: 14

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-11
Form: S-1
Chunk 14
---
 |

| ● | Third-party licensors of our future therapeutic products may be unable to 
 obtain regulatory approval.                                               |

| ● | Failure to obtain regulatory approval in foreign jurisdictions would prevent          
 our product candidates from being marketed in those jurisdictions that deny approval. |

| ● | We may never obtain approval or commercialize such products outside of the 
 U.S.                                                                       |

| ● | The impact of changes to healthcare policy and future healthcare reform legislation 
 is unknown.                                                                         |

Risks Related to Ownership of Our Common Stock and Warrants

| ● | Our failure to meet the listing requirements of The Nasdaq Capital Market 
 could result in a de-listing of our Common Stock.                         |

| ● | We do not expect to pay dividends in the foreseeable future. |

| ● | Our Common Stock market price may never exceed the exercise price of our 
 outstanding warrants.                                                    |

| ● | Holders of our warrants have no rights as stockholders until they exercise 
 their warrants.                                                            |

| ● | The provisions of our outstanding warrants could limit a warrant holder’s 
 ability to choose the judicial forum for disputes.                        |

| ● | The financial and operational projections that we may make from time to time 
 are subject to inherent risks.                                               |

| ● | Our stock price has fluctuated in the past, has recently been volatile, and 
 may be volatile in the future.                                              |

| ● | Our Common Stock has often been thinly traded. |

| ● | An investment in our Company may involve tax implications. |

| ● | Our ability to use our net operating loss carryforwards and certain other 
 tax attributes may be limited.                                            |

| ● | Our Board can designate classes of Preferred Stock without stockholder approval. |

| ● | Provisions in our corporate charter documents and under Delaware law could 
 make an acquisition of the Company more difficult.                         |

| ● | Provisions in our Charter and Amended and Restated (“A&R”)            
 Bylaws could make a merger, tender offer, or proxy contest difficult. |

| ● | Certain provisions of Delaware’s General Corporation Law (“DGCL”) 
 may have anti-takeover effects.                                   |

| ● | Our Charter designates Delaware state or federal courts as the exclusive 
 forum for disputes.                                                      |

| ● | Provisions in our Charter and A&R Bylaws may discourage stockholders 
 from bringing a lawsuit against our directors and officers.          |

| ● | Our management collectively owns a substantial percentage of our Common Stock. |

| ● | If analysts publish